You are here: Industry Insights > Alnylam Pharmaceuticals

News List

Alnylam presents positive phase 3 results from ILLUMINATE-A study of Lumasiran pharmaceutical-business-review
June 10, 2020
Alnylam Pharmaceuticals announced positive Phase 3 results from the ILLUMINATE-A study of lumasiran, an investigational RNAi therapeutic targeting hydroxyacid oxidase 1 (HAO1) ...
Vir, Alnylam to develop VIR-2703 RNAi therapeutic candidate for Covid-19 treatment pharmaceutical-business-review
May 08, 2020
Vir Biotechnology and Alnylam Pharmaceuticals said that they have selected an investigational RNAi therapeutic called VIR-2703 which will be developed for targeting the SARS-CoV-2 genome for the treatment of Covid-19 (novel coronavirus).
Alnylam receives fast track designation for Vutrisiran to treat polyneuropathy of hATTR amyloidosis pharmaceutical-business-review
April 17, 2020
Alnylam Pharmaceuticals, the leading RNAi therapeutics company, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to vutrisiran.
Alnylam’s gene-silencing efforts get $2 billion Blackstone backing expresspharma
April 15, 2020
Alnylam is the first drugmaker to win US approval for a treatment using the Nobel prize-winning RNA interference (RNAi) technology and is currently developing other RNAi drugs to treat a range of conditions, including rare bleeding disorders.
Alnylam seeks FDA approval for lumasiran in primary hyperoxaluria type 1 pharmaceutical-business-review
April 10, 2020
Alnylam Pharmaceuticals has filed an application with the US Food and Drug Administration (FDA) seeking the latter’s approval for lumasiran for the treatment of primary hyperoxaluria type 1 (PH1).
Alnylam and Dicerna form RNAi Therapeutics collaboration on alpha-1 liver disease pharmaceutical-business-review
April 09, 2020
Alnylam Pharmaceuticals and Dicerna Pharmaceuticals have formed a development and commercialization collaboration on investigational RNAi therapeutics.
Alnylam and Dicerna to develop liver disease therapies pharmaceutical-technology
April 08, 2020
Alnylam Pharmaceuticals has partnered with Dicerna Pharmaceuticals to develop and commercialise ribonucleic acid interference (RNAi) therapies to treat alpha-1 antitrypsin (A1AT) deficiency-associated liver disease.
Alnylam Pharmaceuticals and Gen sign distribution agreement in Turkey for ONPATTRO (patisiran) pharmaceutical-business-review
March 30, 2020
Alnylam Pharmaceuticals, Inc., an RNAi therapeutics company, and Gen, a GMP-certified pharmaceutical company specializing in rare diseases ...
Vir Biotechnology and Alnylam partner in fight against Covid-19 pharmaceutical-technology
March 09, 2020
Clinical-stage immunology firm Vir Biotechnology and biopharmaceutical company Alnylam Pharmaceuticals have extended their existing partnership to advance RNAi therapeutics to treat coronavirus infections, including Covid-19.
Alnylam debuts video series to help kids understand rare disease PH1 fiercepharma
September 26, 2019
Each video in the unfolding series will focus on a different child. The first one out shows Isabelle, a young girl talking to her class about her experiences, including having to drink lots of water and sometimes getting painful kidney stones.

Previous page 1 2 Next page